Home » Stocks » ABEO

Abeona Therapeutics Inc. (ABEO)

Stock Price: $1.49 USD -0.01 (-0.67%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 147.57M
Revenue (ttm) 10.00M
Net Income (ttm) -84.23M
Shares Out 92.66M
EPS (ttm) -0.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $1.49
Previous Close $1.50
Change ($) -0.01
Change (%) -0.67%
Day's Open 1.50
Day's Range 1.43 - 1.52
Day's Volume 1,579,434
52-Week Range 0.99 - 3.79

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Refreshed board to bring fresh perspectives, relevant expertise and diverse experience Refreshed board to bring fresh perspectives, relevant expertise and diverse experience

3 weeks ago - GlobeNewsWire

Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -88.89% and -45.95%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Fourth patient treated in pivotal Phase 3 VIITAL™ study of EB-101 in RDEB after successful Type B meeting with FDA

3 weeks ago - GlobeNewsWire

NEW YORK, March 23, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty c...

3 weeks ago - PRNewsWire

CEO appointment provides continuity and reflects company's demonstrated strong operational performance CEO appointment provides continuity and reflects company's demonstrated strong operational performance

3 weeks ago - GlobeNewsWire

NEW YORK and CLEVELAND, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the company will present at th...

1 month ago - GlobeNewsWire

In addition to preservation of neurocognitive development with ABO-102 in MPS IIIA, new clinical results of ABO-102 in MPS IIIA and ABO-101 in MPS IIIB continue to show dose-dependent and sustained redu...

2 months ago - GlobeNewsWire

NEW YORK and CLEVELAND, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it will host a live webinar fo...

2 months ago - GlobeNewsWire

Clinical trial amendment successfully completed for co-primary endpoints of partial wound closure and mean pain reduction Clinical trial amendment successfully completed for co-primary endpoints of part...

2 months ago - GlobeNewsWire

Investors need to pay close attention to Abeona (ABEO) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

NEW YORK and CLEVELAND, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that abstracts detailing new interi...

3 months ago - GlobeNewsWire

Investors need to pay close attention to Abeona (ABEO) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

Abeona Therapeutics Inc's (NASDAQ: ABEO) stock does not reflect the company's in-house manufacturing capabilities and pipeline, according to Cantor Fitzgerald. The Abeona Therapeutics Analyst: Kristen K...

5 months ago - Benzinga

Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of 38.46% and 0.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Conference call scheduled for Tuesday, November 10, 2020 at 8:30 a.m. ET Conference call scheduled for Tuesday, November 10, 2020 at 8:30 a.m. ET

5 months ago - GlobeNewsWire

NEW YORK and CLEVELAND, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, Senior Vice P...

5 months ago - GlobeNewsWire

Steven H. Rouhandeh Appointed as Chairman of the Board of Directors

6 months ago - GlobeNewsWire

NEW YORK and CLEVELAND, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced changes in its executive leaders...

6 months ago - GlobeNewsWire

NEW YORK and CLEVELAND, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company will participat...

7 months ago - GlobeNewsWire

NEW YORK and CLEVELAND and DALLAS, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, and Taysha Gene Therapies, a patient-c...

8 months ago - GlobeNewsWire

Additional patients dosed in RDEB, MPS IIIA and MPS IIIB clinical programs

8 months ago - GlobeNewsWire

NEW YORK and CLEVELAND, July 10, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that two poster presentations rel...

9 months ago - GlobeNewsWire

Abeona (ABEO) restarts patient enrollment in phase III VIITAL study of EB-101 for the treatment of recessive dystrophic epidermolysis bullosa.

9 months ago - Zacks Investment Research

To lead Abeona’s commercial organization, EB-101 commercialization planning and pre-commercial strategy for AAV-based gene therapy programs To lead Abeona’s commercial organization, EB-101 commercializa...

9 months ago - GlobeNewsWire

NEW YORK and CLEVELAND, July 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced recent updates on its clinical pr...

9 months ago - GlobeNewsWire

NEW YORK and CLEVELAND, June 18, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that two abstracts related to its...

10 months ago - GlobeNewsWire

NEW YORK and CLEVELAND, June 17, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced Board of Director appointments th...

10 months ago - GlobeNewsWire

Is (ABEO) Outperforming Other Medical Stocks This Year?

10 months ago - Zacks Investment Research

Abeona Therapeutics is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front

11 months ago - Zacks Investment Research

Abeona's (ABEO) operating expenses are expected to have increased in the first quarter driven by clinical studies on its lead gene therapy candidate.

11 months ago - Zacks Investment Research

NEW YORK and CLEVELAND, April 21, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced it granted options to Brian Pere...

11 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Abeona Therapeutics.

11 months ago - Zacks Investment Research

Company appoints experienced industry leaders Brian Pereira as Executive Chairman and Shawn Tomasello as Independent Board Member Company appoints experienced industry leaders Brian Pereira as Executive...

11 months ago - GlobeNewsWire

Investors need to pay close attention to Abeona Therapeutics (ABEO) stock based on the movements in the options market lately.

11 months ago - Zacks Investment Research

Abeona Therapeutics (ABEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

NEW YORK and CLEVELAND, March 27, 2020 (GLOBE NEWSWIRE) -- The COVID-19 pandemic has created extraordinary challenges across all aspects of healthcare. Many institutions and their brave staff of provi...

1 year ago - GlobeNewsWire

Abeona Therapeutics (ABEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research

Abeona (ABEO) treats first patient in a pivotal study evaluating its gene-corrected cell therapy, EB-101, as a treatment for recessive dystrophic epidermolysis bullosa, a rare connective tissue disorder.

1 year ago - Zacks Investment Research

Majority of potential study participants have been pre-screened

1 year ago - GlobeNewsWire

Can these high-flying biotech stocks keep up their sizzling momentum?

Other stocks mentioned: AVDL, RCUS
1 year ago - The Motley Fool

Investors need to pay close attention to Abeona (ABEO) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

The US dollar drew support from a healthy domestic economy, and Fed's cautiously optimistic stance about holding interest rates despite the coronavirus outbreak.

Other stocks mentioned: APLT, EBF, ONTX, PTI
1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Abeona Therapeutics.

1 year ago - Zacks Investment Research

Neurocognitive development of young MPS IIIA patients preserved up to two years post ABO-102 treatment

1 year ago - GlobeNewsWire

NEW YORK and CLEVELAND, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the United States Patent and...

1 year ago - GlobeNewsWire

Study open for enrollment and patient screening underway at Stanford University

1 year ago - GlobeNewsWire

Abeona Therapeutics: Speculative Buy After Financing

1 year ago - Seeking Alpha

NEW YORK and CLEVELAND, Dec. 24, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the closing of its underwritten p...

1 year ago - GlobeNewsWire

The small-cap company announced the pricing of a public stock offering.

1 year ago - The Motley Fool

Investors need to pay close attention to Abeona Therapeutics (ABEO) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

About ABEO

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for th... [Read more...]

Industry
Biotechnology
IPO Date
Sep 19, 1980
CEO
Joao Siffert
Employees
76
Stock Exchange
NASDAQ
Ticker Symbol
ABEO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for ABEO stock is "Buy." The 12-month stock price forecast is 5.67, which is an increase of 280.54% from the latest price.

Price Target
$5.67
(280.54% upside)
Analyst Consensus: Buy